8:44 AM
 | 
Oct 09, 2018
 |  BC Extra  |  Company News

FDA reviewers doubt benefits of Trevena's analgesic over morphine

Trevena Inc. (NASDAQ:TRVN) was off $1.91 (64%) to $1.07 on Tuesday after FDA reviewers expressed doubts that the company’s Olinvo oliceridine (TRV130) offered a benefit over morphine, according to briefing documents released ahead of a planned advisory committee meeting.

In "the most clinically relevant" efficacy analysis of two Phase III studies, the reviewers wrote, morphine led to significantly greater reductions in pain intensity than both doses of Olinvo for which Trevena is seeking approval. The...

Read the full 354 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >